Merck & Co IncNYSE
Historical Stock Data
|52 Week High|
|52 Week Low|
What Analysts Recommend for Merck and AstraZeneca in June
Merck & Co. (MRK) is up 8.49%, and AstraZeneca (AZN) is up 5.08% in 2019 on a year-to-date basis. Merck continues to ride on the success of its leading immuno-oncology drug, Keytruda. AstraZeneca’s oncology drugs Tagrisso and Lynparza have emerged as key revenue drivers for it in 2019.